France

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A French spending bill that would tax drug company turnover would create a “catastrophic competitiveness gap” between France and its European neighbors, warns Leem, the French pharmaceutical industry group.

Economic woes in France mean that tough and unpopular choices impacting the biopharmaceutical industry are inevitable, according to industry expert Alexandre Regniault.

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Partners Formycon and Teva are hoping to gain an advantage in the European ranibizumab market by launching a unique pre-filled syringe formulation of their partnered Lucentis biosimilar.

Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

France’s social security financing bill for 2026 is due to be presented in parliament in the coming weeks.

Formycon has signed a further licensing deal in Europe, this time for its Eylea biosimilar that holds a pan-European marketing authorization.